Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

Gilead Sciences SWOT & PESTLE Analysis

ID : 52614653| Jan 2020| 15 pages

COMPANY PROFILE -Gilead Sciences

Business Sector :Pharmaceutics and Biotechnology

Operating Geography :United States, North America, Global

About Gilead Sciences :

Gilead Sciences, Inc. is an American biopharmaceutical company that focuses primarily on antiviral drugs used in the treatment of Hepatitis B, Hepatitis C, HIV and influenza, including Sovaldi and Harvoni. It is headquartered at Foster City, California, United States. It was founded in June 1987 by Michael L. Riordan with the help of three core scientific advisers, Peter Dervan (Caltech), Doug Melton (Harvard) and Harold M. Weintraub (Fred Hutchinson Cancer Research Centre). The company has expanded to multiple drug segments through a series of strategic acquisitions starting from NeXstar Pharmaceuticals, Corus Pharma Inc. (2006), Raylo Chemicals Inc. (2006), CV Therapeutics (2009), CGI Pharmaceuticals (2010). The company made three acquisitions alone in 2015 namely: Phenex Pharmaceuticals, EpiTherapeutics and Galapagos NV. The company’s product portfolio includes more than 25 products including complete treatment regiments for HIV and Hepatitis C virus.
Gilead Sciences mission statement reads “To discover, develop and commercialize innovative therapeutics in the areas of unmet medical needs that improve patient care.” The research based, biopharmaceutical Company’s vision is “To advance therapeutics against life-threatening diseases worldwide.” Gilead Sciences, Inc’s USP or unique selling proposition lies in its strive to help improve the lives of people with life-threatening illnesses around the world by researching, developing and commercializing anti-virial drugs for the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Gilead Sciences Revenue :


$ 22.1 Billion – FY ending 31st Dec 2018
$ 26.1 Billion – FY ending 31st Dec 2017

Competitive Analysis of Gilead Sciences

SWOT
PESTLE
The SWOT analysis of Gilead Sciences is presented below:
Strengths
Weaknesses
1. Strong Brand Portfolio
2. Research and Development Orientation
3. Investments in process automation
4. Strategic Acquisitions and mergers
1. High dependence on HIV and HCV sales
2. Inability to accurately predict demand
Opportunities
Threats
1. High Growth potential of Biopharmaceutical industry
2. Usage of Industry 4.0 Technology
1. Patent Protection and Certain Challenges
2. Regulation of Manufacturing Process
3. Complexity of Biopharma supply chain and operations
4. High competition in the industry
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Detailed SWOT Analysis of Gilead Sciences

 

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

1. High Growth potential of Biopharmaceutical Industry: The biopharma sector has undergone momentous growth in the recent decade. It has scaled a 6,250 % growth, climbing from an annual revenue of approximately $ 4.4 billion in 1990 to $ 275 billion in 2018. This sector can be considered matured and the trends are relatively stable. The advantage of having a highly regulated market is that this environment is relatively easy to track over time, and the data can be used to access future movement more accurately. The ongoing industry trends support an optimistic view of this sector and it includes: more biopharma facilities worldwide (both major markets and Asia), more revenue and added-value for patients from innovations and processes. It also opens new opportunities of flexible manufacturing facilities including manufacturing of multiple products, automation, process control and monitoring. The current future of this industry is exciting with new technologies and markets, such as biosimilars, continuous processing, cellular and gene therapies and many more.

2. Usage of Industry 4.0 Technology: The biopharma manufacturing industry must become more streamlined and cost efficient to tackle increasing globalization and complex regulations. Adoption of Industry 4.0 technologies can provide a potential solution and there is scope to scale up implementation of these technologies in this sector. However, there are also associated challenges which can be attributed to implementation challenges in highly regulated markets, lack of knowledge required for implementation of these technologies in a scalable way within the existing systems and limited visibility of what facility should look like to be classified as best in class and if value exists for operations. However, to progress forward and implement Industry 4.0 technologies a number of factors needs to be addressed, like, risk mitigation of these technologies in highly regulated environment, quality improvement and assurance to meet the regulatory scrutiny, flexibility and scalability as per the requirement, increased productivity and increased scale-up speed and speed to market and most importantly increased innovation possibilities with the availability of new technology.

Threat

This section is available only in the 'Complete Report' on purchase.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Gilead Sciences Analysis Report

1. Gilead Sciences annual report 2018 - http://www.annualreports.com/HostedData/AnnualReports/PDF/NASDAQ_GILD_2018.pdf

2. Gilead Sciences company website - https://www.gilead.com/

3. Gilead Sciences company profile - https://money.cnn.com/quote/profile/profile.html?symb=GILD

4. What to Expect from Johnson & Johnson and Gilead Sciences’ EPS - https://articles2.marketrealist.com/2019/06/what-to-expect-from-johnson-johnson-and-gilead-sciences-eps/

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Gilead Sciences SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). Gilead Sciences SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/gilead-sciences/ [Accessed 08 Aug, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Gilead Sciences SWOT and PESTLE analysis has been conducted by Pallavi Roy and reviewed by senior analysts from Barakaat Consulting.

Copyright of Gilead Sciences SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
Gilead Sciences SWOT & PESTLE Analysis
Price : USD 12.53